Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

IDEAYA: OptimUM-02 success triggers RTOR NDA; cash runway to 2030

Aug 4, 2026, 6:06 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Material regulatory milestone (RTOR NDA) and positive pivotal trial data typically drive near-term upside; additional catalysts (ESMO updates, Roche collaboration, cash runway) reinforce upside but execution/approval risk remains.

AI summary

What happened, with direct paths to the underlying reporting

IDEAYA reported Q2 2026 results noting OptimUM-02 in metastatic uveal melanoma met the primary endpoint, enabling a real-time NDA under RTOR with a completion target in H2 2026. Updated OptimUM-01/09 data will be shown at ESMO, while Roche collaboration on IDE892+RG6505 expands MTAP-deleted cancer programs. The company holds about $1.24B in cash with runway through 2030, supporting multiple data milestones through 2026–2027.

OptimUM-02 met primary endpoint; NDA filing under RTOR with expected H2 2026.
ESMO to present OptimUM-01/OptimUM-09 updates; IDE849 data at ESMO.
Roche collaboration targets IDE892+RG6505 in MTAP-deleted pancreatic cancer; Phase 1 planned H2 2026.
Cash ~$1.24B as of 6/30/2026; runway into 2030 unchanged.
R&D Day in Q4 2026 focusing on MTAP/CDKN2A, KRAS, pancreatic cancer.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.